922732-12-5

Basic information

• Product Name: 4-nitrobenzoic acid (3R,5S)-5-((R)-1-ethoxycarbonyl-2-vinylcyclopropylcarbamoyl)pyrrolidin-3-yl ester
• Synonyms: 4-nitrobenzoic acid (3R,5S)-5-((R)-1-ethoxycarbonyl-2-vinylcyclopropylcarbamoyl)pyrrolidin-3-yl ester
• CAS NO: 922732-12-5
• Molecular Weight: 417.419
• Mol File: 922732-12-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-nitrobenzoic acid (3R,5S)-5-((R)-1-ethoxycarbonyl-2-vinylcyclopropylcarbamoyl)pyrrolidin-3-yl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-nitrobenzoic acid (3R,5S)-5-((R)-1-ethoxycarbonyl-2-vinylcyclopropylcarbamoyl)pyrrolidin-3-yl ester(922732-12-5)
• EPA Substance Registry System: 4-nitrobenzoic acid (3R,5S)-5-((R)-1-ethoxycarbonyl-2-vinylcyclopropylcarbamoyl)pyrrolidin-3-yl ester(922732-12-5)

Safety Data

• Hazardous Substances Data: 922732-12-5(Hazardous Substances Data)

Upstream product

• 922732-11-4 (2S,4R)-2-((1R,2S)-1-ethoxycarbonyl-2-vinylcyclopropylcarbamoyl)-4-(4-nitrobenzoyloxy)-pyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 922732-13-6 4-nitrobenzoic acid (3R,5S)-5-((1R,2S)-1-ethoxycarbonyl-2-vinylcyclopropylcarbamoyl)-1-[hept-6-enyl-(4-methoxybenzyl)carbamoyl]pyrrolidin-3-yl ester 

Relevant articles and documents

HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES

Compounds of the Formula (I) including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof;usefulas HCV inhibitors; processes for preparing these compounds as well a

MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by ------) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR6, -NH-SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, C1-6alkoxy- carbonyl, amino, azido, mercapto, C1-6alkylthio, polyhaloC1-6alkyl, aryl or Het; W is aryl or Het; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 - 4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1 -3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.